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Summary
Background.  —  Antiplatelet  therapies,  including  prasugrel,  are  a  cornerstone  in  the  treatment
of ST-segment  elevation  myocardial  infarction  (STEMI),  but  are  associated  with  a  bleeding  risk.
This risk  has  been  evaluated  in  randomized  trials,  but  few  data  on  real-world  patients  are
available.
Aim. —  To  evaluate  prasugrel  safety  in  real-world  patients  with  STEMI.
Methods.  —  Consecutive  patients  with  STEMI  were  recruited  over  1  year.  Follow-up  was  done  at  3
months and  1  year  to  evaluate  prasugrel  safety  from  hospital  discharge  to  the  STEMI  anniversary
date. The  primary  outcome  was  occurrence  of  any  major  bleeding  according  to  the  Bleeding
Academic Research  Consortium  (BARC)  3  or  5  deﬁnitions,  or  minor  bleeding  according  to  the
BARC 2  deﬁnition.
Results.  —  Overall,  1083  patients  were  recruited.  Compared  to  patients  treated  with
aspirin +  clopidogrel,  patients  treated  with  aspirin  +  prasugrel  had  fewer  BARC  3  or  5  bleed-
ings (two  [0.4%]  patients  vs.  nine  [1.8%]  patients;  P  =  0.04),  but  more  BARC  2  bleedings  (45
[9.3%] patients  vs.  20  [4.0%]  patients;  P  <  0.001).  The  baseline  characteristics  of  prasugrel-
and clopidogrel-treated  patients  differed  because  the  former  were  carefully  selected  (younger,
higher body  mass  index,  less  frequent  history  of  stroke).  In  the  overall  population,  rates  of
in-hospital and  out-of-hospital  major  bleeding  were  2.6%  (n  =  28)  and  1.3%  (n  =  13),  respectively.
Conclusion.  —  The  rate  of  major  bleeding,  particularly  out-of-hospital  bleeding,  in  patients
treated with  prasugrel  is  low  within  1  year  after  a  STEMI.  Accurate  selection  of  patient  candi-
dates for  prasugrel  is  likely  to  have  reduced  the  risk  of  bleeding.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
MOTS  CLÉS
Prasugrel  ;
Saignements  ;
Syndrome  coronarien
aigu  avec
sus-décalage  du
segment  ST  ;
Patients  dans  la
« vraie  vie  »
Résumé
Contexte.  —  Les  traitements  antiplaquettaires,  dont  le  prasugrel,  sont  un  élément  majeur  dans
le traitement  du  syndrome  coronarien  aigu  avec  sus-décalage  du  segment  ST  (SCA  ST+)  mais
entraînent  un  sur-risque  hémorragique.  Ce  risque  a  été  évalué  dans  des  essais  cliniques  ran-
domisés mais  il  existe  peu  de  données  dans  la  « vraie  vie  ».
Objectif.  —  Évaluer  la  sécurité  du  prasugrel  chez  des  patients  adressés  pour  un  syndrome  coro-
narien aigu  avec  sus-décalage  du  segment  ST  dans  la  « vraie  vie  ».
Méthodes.  —  Les  patients  avec  SCA  ST+  ont  été  recrutés  pendant  un  an  et  le  suivi  a  été  effec-
tué, par  téléphone,  3  mois  et  1  an  après  le  SCA  ST+  aﬁn  d’évaluer  la  sécurité  du  prasugrel,
en particulier  pendant  la  période  post-hospitalière.  Le  critère  d’évènement  principal  était  la
survenue d’un  évènement  hémorragique  majeur  déﬁni  selon  la  classiﬁcation  Bleeding  Academic
Research Consortium  (BARC)  3  ou  5  ou  d’un  évènement  hémorragique  mineur  déﬁni  selon  la
classiﬁcation  BARC  2.
Résultats.  —  Mille  quatre-vingt-trois  patients  ont  été  recrutés.  Les  patients  traités  par
aspirine +  clopidogrel  avaient  moins  de  saignements  BARC  3  ou  5  que  les  patients  traités  par
aspirine +  prasugrel  (9  patients,  1,8  %  vs  2  patients,  0,4  %  ;  p  =  0,04)  mais  ils  avaient  plus  de
saignements  BARC  2  (20  patients,  4,0  %  vs  45  patients,  9,3  %  ;  p  <  0,001).  Les  caractéristiques
des patients  traités  par  prasugrel  étaient  différentes  des  patients  traités  par  clopidogrel  car  la
sélection était  attentive  :  patients  plus  jeunes,  indice  de  masse  corporelle  plus  élevé,  moins
d’antécédent  d’accident  vasculaire  cérébral.  Les  pourcentages  de  saignement  intra-hospitalier
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majeur  et  de  saignement  extra-hospitalier  majeur  étaient  respectivement  de  2,6  %  (n  =  28)  et
1,3 %  (n  =  13).
Conclusion.  —  Les  saignements  majeurs,  en  particulier  extra-hospitaliers,  sont  peu  fréquents
chez les  patients  traités  par  prasugrel  dans  l’année  qui  suit  un  SCA  ST+.  Une  sélection  attentive
des patients  pouvant  bénéﬁcier  du  prasugrel  peut  expliquer  une  diminution  de  ce  risque.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Cardiovascular  diseases,  including  acute  myocardial  infarc-
tion,  are  currently  one  of  the  leading  causes  of  death  in
Western  countries.  Medical  therapies  focus  on  anticoagula-
tion  and  platelet  inhibition  to  reduce  the  risk  of  thrombotic
events  and  improve  ischaemic  outcomes  in  patients  with
ST-segment  elevation  myocardial  infarction  (STEMI).  These
therapies,  coupled  with  early  use  of  cardiac  catheteriza-
tion  and  revascularization,  reduce  the  rate  of  death  and
reinfarction,  but  carry  a  bleeding  risk.  Indeed,  bleeding  is
the  most  common  non-cardiac  complication  of  antithrom-
botic  therapy  in  acute  coronary  syndromes  (ACS),  and  has
been  associated  with  adverse  outcomes,  including  myocar-
dial  infarction,  stroke  and  death  [1,2].  Thus,  clinicians  must
balance  antithrombotic  treatment  efﬁcacy  in  preventing
ischaemic  events  with  the  need  to  minimize  the  risk  of  seri-
ous  bleeding  complications.  Bleeding  is  even  more  frequent
when  percutaneous  coronary  intervention  (PCI)  is  performed
in  the  context  of  acute  STEMI,  compared  with  bleeding  com-
plicating  an  elective  procedure  [3].
Several  new  antiplatelet  therapies,  including  prasugrel,
have  been  evaluated  in  randomized  trials;  they  reduce  the
ischaemic  risk  but  are  associated  with  an  increased  risk  of
major  bleeding.  In  patients  with  STEMI  undergoing  PCI,  pra-
sugrel  is  more  effective  than  clopidogrel  in  the  prevention
of  ischaemic  events,  without  excess  bleeding  [4].  However,
there  are  few  data  on  the  safety  of  new  antiplatelet  agents
and  bleeding  risk  within  1  year  after  STEMI  in  real-world
patients  [5—7].  The  Bleeding  and  Myocardial  Infarction
(Bleed-MI)  Study  sought  to  evaluate  the  safety  of  prasugrel
in  real-world  patients  with  STEMI,  from  hospital  discharge
to  the  anniversary  date  of  the  STEMI.  Safety  was  assessed
by  analysing  out-of-hospital  bleeding.
Methods
Study patients
From  1st  April  2011  to  31st  March  2012,  patients  were
included  if  they  had  a  STEMI  and  were  hospitalized  in
any  of  the  nine  primary  percutaneous  intervention  cen-
tres  in  Brittany,  France,  within  24  hours  after  the  onset
of  symptoms.  There  were  no  exclusion  criteria.  Data  were
recorded  in  the  ORBI-registry,  which  was  approved  by  the
Commission  nationale  informatique  et  liberté.  All  patients
were  informed  of  the  aims  of  the  study  and  could  request
to  be  excluded.  The  follow-up  interviews  were  conducted
by  telephone  by  research  nurses  at  3  months  and  1
year.  The  follow-up  questionnaire  elicited  key  information
about  antiplatelet  and  anticoagulation  therapies,  medical
s
d
r
rreatment  and  occurrence  of  bleeding  or  ischaemic  events.
n  case  of  bleeding  or  ischaemic  events,  the  hospitaliza-
ion  reports  and  all  medical  examination  results  (e.g.  blood
ests,  medical  imaging,  etc.)  were  recovered,  so  that  all
ata  were  centralized.  Patients  for  whom  follow-up  data
ere  lacking  were  considered  lost  to  follow-up.
eﬁnitions
he  Bleeding  Academic  Research  Consortium  (BARC)  [8]  was
sed  to  deﬁne  bleeding  events  occurring  within  1  year  after
 STEMI.  BARC  3  or  5  bleedings  were  considered  major
leedings;  BARC  2  bleedings  were  considered  minor  bleed-
ngs.  BARC  1  bleedings  were  not  collected  because  they  do
ot  require  treatment  by  a  healthcare  professional;  thus,
heir  collection  would  not  have  been  exhaustive.  Coronary
rtery  bypass  graft  (CABG)-related  bleedings  (BARC  4  bleed-
ngs)  were  not  analysed.  Bleeding  rates  were  also  deﬁned
ccording  to  thrombolysis  in  myocardial  infarction  (TIMI)
eﬁnitions  [9]. Cardiovascular  death  was  any  death  result-
ng  from  a  new  ACS,  severe  cardiac  arrhythmia,  refractory
ongestive  heart  failure,  cardiogenic  shock,  stroke,  sudden
eath  or  unwitnessed  death.  Acute  myocardial  infarction
as  deﬁned  in  accordance  with  the  universal  deﬁnition  of
yocardial  infarction  proposed  in  2012  [10].  Evaluation  for
tent  thrombosis  was  performed  according  to  the  Academic
esearch  Consortium  criteria  [11].
tudy outcomes
he  primary  outcome  was  the  occurrence  of  any  minor  or
ajor  bleeding  between  discharge  and  the  end  of  follow-
p  at  1  year.  A  ‘‘bleeding  events’’  committee  validated,
lassiﬁed  and  located  the  site  of  each  bleeding  event,
sing  telephone  interviews,  the  hospitalization  reports  and
he  medical  examination  results.  Prespeciﬁed  secondary
utcomes  included  in-hospital  major  bleeding  and  rates
f  premature  discontinuation  (transitory  or  not)  of  any
ntithrombotic  treatment  after  a  bleeding  complication.
he  rates  of  major  adverse  cardiac  events,  including  cardio-
ascular  death,  non-fatal  STEMI,  non-fatal  stroke  and  stent
hrombosis,  were  calculated.
tatistical methods
ata  description  started  with  displaying  the  number  of
atients  with  haemorrhage  or  who  were  censored  with  no
vent  12  months  after  myocardial  infarction.  Descriptive
tatistics  included  mean  and  standard  deviation  for  normally
istributed  continuous  variables,  median  and  interquartile
ange  otherwise,  and  number  and  percentage  for  catego-
ical  variables.  Comparisons  according  to  dual  antiplatelet
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egimen  on  discharge  used  the  Chi-square  test  or  Fisher’s
xact  test  for  categorical  variables  and  Student’s  t  test  or
he  Wilcoxon  test  for  continuous  variables.  For  the  main
utcome,  a  survival  analysis  was  used.  Only  one  event  per
ubject  could  occur  in  the  analysis.
First,  univariate  (marginal)  Wald  test  statistics  using  the
ox  model  were  performed  for  each  covariate.  Then,  mul-
ivariable  modelling  was  completed  with  a  Cox  proportional
azards  model  that  contained  all  covariates  signiﬁcantly
ssociated  in  the  univariate  analyses  at  the  P  =  0.15  level.  We
sed  a  hand-made  stepwise  backward  elimination  process:
ollowing  the  ﬁt  of  the  multivariable  model,  we  used  the  P-
alues  from  the  Wald  tests  of  the  individual  coefﬁcients  to
dentify  covariates  that  might  be  deleted  from  the  model.
he  linearity  of  the  relationship  between  continuous  covari-
tes  was  not  rejected  except  for  haematocrit  value  when
onsidering  death;  a  cut-off  at  37.4%  was  identiﬁed  from
artingale  residuals  analysis.  In  addition,  the  graphical  and
umerical  methods  derived  from  cumulative  sums  of  martin-
ale  residuals  over  follow-up  times  or  the  covariate  values  of
in  et  al.  [12]  were  used  for  checking  the  proportional  haz-
rd  assumption.  For  all  statistical  analyses,  SAS  software,
ersion  9.3  (SAS  Institute,  Cary,  NC,  USA)  was  used.
esultstudy patients and in-hospital events
verall,  1083  consecutive  patients  with  STEMI  from  nine
entres  in  Brittany  were  recruited  from  1st  April  2011  to
g
2
l
(
Table  1 Baseline  characteristics  of  the  patients  and  occurren
Populatio
(n  =  1083)
Age  (years) 62.7  ±  14
Women  282  (26.0
Body  weight  (kg) 75.5  ±  15
BMI  (kg/m2)  26.3  ±  4.3
Cardiovascular  risk  factors
Habitual  smoker  439  (40.5
Arterial  hypertension 460  (42.5
Diabetes  mellitus  147  (13.6
Other  medical  history
Stroke/TIA  34  (3.1)  
Chronic  renal  disease  23  (2.1)  
Gastroduodenal  ulcer  34  (3.1)  
Initial  use  of  glycoprotein  IIb/IIIa  inhibitors  489  (45.2
Occurrence  of  bleeding  events  during  follow-up
Total  
BARC  2  
BARC  3  
BARC  5  
BARC  3  +  5 
Data are expressed as mean ± standard deviation or number (%). BARC:
TIA: transient ischaemic attack.R.  Bacquelin  et  al.
1st  March  2012.  No  patient  asked  to  be  excluded.  Follow-
p  occurred  from  1st  July  2011  to  31st  March  2013.  The
aseline  characteristics  of  the  patients  are  summarized
n  Table  1. Coronary  angiography  was  performed  in  1060
97.9%)  patients,  with  radial  access  in  564  (53.2%)  patients,
nd  angioplasty  was  performed  in  974  (89.9%)  patients;
1.6%  (n  =  892)  of  stented  patients  received  at  least  one
tent,  and  22.5%  (n  =  219)  of  stented  patients  had  at  least
ne  drug-eluting  stent.  Glycoprotein  IIb/IIIa  inhibitors  were
sed  in  489  (45.2%)  patients.
In-hospital  BARC  3  bleeding  was  observed  in  28  (2.6%)
atients;  there  was  no  in-hospital  BARC  5  bleeding  (Table  2).
mong  these  28  patients,  bleeding  was  attributed  to  a  vas-
ular  access  site  in  seven  (25%)  patients.  In-hospital  BARC
 bleedings  were  not  recorded.  Switches  from  prasugrel  to
lopidogrel  occurred  in  48  (4.4%)  patients,  mainly  for  pre-
aution  of  use.
Because  of  51  (4.7%)  in-hospital  deaths,  1032  patients
ere  analysed  for  follow-up.  At  discharge,  1021  (98.9%)
atients  were  treated  with  aspirin,  513  (49.7%)  with  clo-
idogrel,  484  (46.9%)  with  prasugrel  and  52  (5.0%)  with  a
itamin  K  antagonist  (VKA).  Overall,  956  (92.6%)  patients
ere  treated  with  dual  antiplatelet  therapy  alone,  and
2  (3.1%)  were  treated  with  triple  antithrombotic  ther-
py  (aspirin  +  clopidogrel  +  a  VKA  or  aspirin  +  prasugrel  + a
KA).  Twenty-three  (2.2%)  patients  were  treated  with
nly  one  antiplatelet  agent:  aspirin  (n  =  19),  clopido-
rel  (n  =  3)  and  prasugrel  (n  =  1).  Data  were  missing  for
3  (2.2%)  patients.  A  total  of  26  (2.5%)  patients  were
ost  to  follow-up  at  the  end  of  the  follow-up  period
Fig.  1).
ce  of  bleeding  events  during  the  follow-up.
n Aspirin  +  clopidogrel
(n  =  505)
Aspirin  +  prasugrel
(n  =  483)
P
.0  67.3  ±  14.2  55.9  ±  10.2  <0.0001
)  171  (33.9)  67  (13.9)  <0.0001
.0 71.2  ±  14.7  80.7  ±  13.4  <0.0001
 25.4  ±  4.3  27.2  ±  4.0  <0.0001
)  159  (31.7)  254  (52.6)  <0.0001
)  252  (49.9)  150  (31.1)  <0.0001
)  72  (14.3)  59  (12.2)  0.34
20  (4.0)  5  (1.0)  0.0034
15  (3.0)  5  (1.0)  0.0309
11  (2.2)  7  (1.4)  0.39
)  233  (46.1)  233  (48.2)  0.51
23  (4.6)  43  (8.9)  0.0110
15  (3.0)  42  (8.7)  0.0003
6  (1.2)  1  (0.2)  0.13
2  (0.4)  0  (0)  0.50
8  (1.6)  1  (0.2)  0.0389
 Bleeding Academic Research Consortium; BMI: body mass index;
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Table  2  Chronology  of  in-hospital  and  out-of-hospital
bleeding.
In-hospital
bleeding
(n  =  1083)
Out-of-hospital
bleeding
(n  =  1006)
BARC  deﬁnition
BARC  2  bleeding Not  collected 66  (6.6)
BARC  3  bleeding 28  (2.6) 11  (1.1)
BARC  3a  17  (1.6)  6  (0.6)
BARC  3b  9  (0.8)  3  (0.3)
BARC  3c  2  (0.2)  2  (0.2)
BARC  5  bleeding  0  (0)  2  (0.2)
BARC  5a  0  (0)  2  (0.2)
BARC  5b  0  (0)  0  (0)
BARC  3  or  5  bleeding  28  (2.6)  13  (1.3)
TIMI  deﬁnition
TIMI  major  bleeding  10  (0.9)  6  (0.6)
TIMI  major  or  minor
bleeding
22  (2.0)  13  (1.3)
Data are expressed as number (%). BARC: Bleeding Academic
F
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tResearch Consortium; TIMI: thrombolysis in myocardial
infarction.
Out-of-hospital bleedingOut-of-hospital  major  bleeding  according  to  BARC  3  or
5  deﬁnitions  occurred  in  13  of  1006  (1.3%)  patients
(Table  2).  Out-of-hospital  major  bleeding  according  to  the
p
s
t
Figure 1. Flow-chart.igure 2. Patients with Bleeding Academic Research Consortium
 or 5 bleeding during the follow-up period.
IMI  deﬁnition  occurred  in  6  of  1006  (0.6%)  patients.  In  total,
ARC  3  or  5  bleeding,  including  in-hospital  bleeding,  was
bserved  in  41  (3.8%)  patients,  and  occurred  during  the  ﬁrst
rimester  in  33  patients  (80.5%  of  major  bleedings;  Fig.  2).
he  most  frequent  out-of-hospital  BARC  3  or  5  bleeding  sites
ere  gastrointestinal  (n  =  6)  and  cerebral  (n  =  4).  The  most
requent  out-of-hospital  BARC  2  bleeding  sites  were  ear,
ose  and  throat  (n  =  26),  cutaneous  (n  =  14)  and  gastroin-
estinal  (n  =  12;  Table  3).Patients  treated  with  aspirin  +  prasugrel  compared  with
atients  treated  with  aspirin  +  clopidogrel  had  statistically
igniﬁcantly  less  BARC  3  or  5  bleeding  (0.4%  vs.  1.8%,  respec-
ively;  P  =  0.04),  but  more  BARC  2  bleeding  (9.3%  vs.  4.0%,
36  R.  Bacquelin  et  al.
Table  3  Location  of  out-of-hospital  bleeding  and  vascular  access.1.
Location  of  bleeding  BARC  classiﬁcation  Radial  access
BARC  2 BARC  3 BARC  5
Cutaneous  14  1  0  5  (33)
Gastrointestinal  12  6  0  13  (72)
Cerebral  0  2  2  0  (0)
Ear,  nose  and  throat 26  0  0  15  (57)
Respiratory  tract  5  0  0  2  (40)
Urinary  tract  5  0  0  4  (80)
Other  4  2  0  3  (50)
Total  66  11  2  42  (53)
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espectively;  P  <  0.001).  Among  the  988  patients  treated
ith  dual  antiplatelet  therapy,  the  baseline  characteristics
f  patients  treated  with  prasugrel  were  different  to  those  of
atients  treated  with  clopidogrel  (Table  1).  Patients  treated
ith  aspirin  +  prasugrel  were  more  often  male,  younger,  with
 higher  body  mass  index  and  less  frequent  history  of  arterial
ypertension,  stroke  or  transient  ischaemic  attack.  Patients
reated  with  prasugrel  were  carefully  selected:  eight  (1.7%)
rasugrel-treated  patients  were  aged  ≥75  years,  while  193
37.6%)  clopidogrel-treated  patients  were  aged  ≥75  years.
hirteen  (2.7%)  prasugrel-treated  patients  weighed  <60  kg,
hereas  107  (20.8%)  clopidogrel-treated  patients  weighed
60  kg.  Five  (1.0%)  prasugrel-treated  patients  had  a  history
f  stroke  or  transient  ischaemic  attack  compared  with  19
3.7%)  clopidogrel-treated  patients.  In  the  Bleed-MI  Study,
he  rate  of  major  out-of-hospital  bleeding  was  low,  so  it
educed  the  statistical  power  for  detecting  any  clinical  and
iological  predictors  of  bleeding  events.
ntithrombotic agents
mong  the  79  patients  with  out-of-hospital  BARC  2,  3  or  5
leeding,  25  patients  were  treated  with  aspirin  +  clopidogrel
5.2%  of  patients  using  this  combination),  45  with
spirin  +  prasugrel  (9.5%  of  patients  using  this  combi-
ation),  two  with  aspirin  +  a  VKA  (14.3%  of  patients
sing  this  combination),  four  with  aspirin  +  clopidogrel  +  a
KA  (16%  of  patients  using  this  combination),  two  with
spirin  +  prasugrel  +  a  VKA  (28.6%  of  patients  using  this  com-
ination)  and  one  with  aspirin  alone  (5.3%  of  patients  using
spirin  alone).  Hence,  7.3%  of  patients  (70/956)  treated
ith  two  antiplatelet  agents  experienced  out-of-hospital
leeding,  and  18.7%  of  patients  (6/32)  treated  with  three
ntithrombotic  agents  experienced  out-of-hospital  bleed-
ng.  Moreover,  0.9%  of  patients  (9/956)  treated  with  dual
ntiplatelet  therapy  alone  experienced  BARC  3  or  5  out-of-
ospital  bleeding,  and  7.7%  (4/52)  of  patients  treated  with
 VKA  experienced  BARC  3  or  5  out-of-hospital  bleeding.
nticoagulant  agents  therefore  had  an  important  role  in  the
ccurrence  of  major  bleeding  events.iscontinuation of medication
leeding  (BARC  2,  3  or  5)  led  to  temporary  or  deﬁnitive  dis-
ontinuation  of  at  least  one  antithrombotic  agent  in  27  of
T
a
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9  patients  who  had  bleeding.  Among  these  patients,  ﬁve
ad  prasugrel  replaced  by  clopidogrel.  The  discontinuation
as  deﬁnitive  for  20  patients  (74%  of  patients  with  discon-
inuation  of  treatment):  aspirin  in  two  patients,  clopidogrel
n  eight  patients,  prasugrel  in  eight  patients,  a  VKA  in  one
atient  and  prasugrel  +  a VKA  in  one  patient.  The  discontin-
ation  was  temporary  for  seven  patients:  aspirin  in  three
atients,  clopidogrel  in  one  patient,  aspirin  +  clopidogrel  in
ne  patient  and  a  VKA  in  two  patients.  The  mean  duration  of
ntithrombotic  agent  discontinuation  was  6.5  months  (±  4.5
onths).  Antithrombotic  agents  were  interrupted  before
onth  6  in  13  (48.1%)  patients,  after  month  6  in  14  (51.9%)
atients  and  beyond  month  9  in  11  (40.7%)  patients.
The  most  frequent  bleeding  sites  leading  to  treatment
iscontinuation  were  gastrointestinal  (25.9%),  ear,  nose  and
hroat  (25.9%)  and  cutaneous  (25.9%).  Interestingly,  bleed-
ng  that  led  to  discontinuation  of  medications  was  not  major
n  most  cases;  in  fact,  74.1%  of  those  bleeds  were  BARC  2,
4.8%  were  BARC  3a,  3.7%  were  BARC  3b  and  7.4%  were
ARC  3c.  No  ischaemic  event  was  observed  after  discontin-
ation  of  antithrombotic  medications.  No  relationship  was
ound  between  bleeding  occurrence  and  increased  risk  of
schaemic  event.
actors predictive of death
orty-four  (4.4%)  patients  died  from  any  cause  during
ollow-up.  From  the  multivariable  analysis,  the  factors  inde-
endently  associated  with  death  included  age  (hazard  ratio
HR]:  2.2,  95%  conﬁdence  interval  [CI]:  1.6—3.0;  P  <  0.001),
igns  of  congestive  heart  failure  on  presentation  (HR:  4.1,
5%  CI:  2.1—8.1;  P  <  0.001)  and  baseline  haematocrit  ≤37.4%
HR:  0.3,  95%  CI:  0.2—0.6;  P  <  0.001).  Although  any  BARC  3  or
 bleeding  predicted  death  in  the  univariate  analysis,  these
actors  did  not  remain  independent  predictors  of  death  after
djustment  for  other  covariates.  This  was  also  true  for  sex,
eight,  body  mass  index,  history  of  hypertension,  prior  coro-
ary  heart  disease,  prior  chronic  renal  disease,  baseline
reatinine  and  duration  of  hospitalization.
ut-of-hospital ischaemic eventshe  rate  of  out-of-hospital  major  adverse  cardiac  events
mong  patients  with  BARC  2,  3  or  5  bleeding  was  7.6%  (n  =  6).
here  was  no  statistically  signiﬁcant  difference  compared
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with  the  entire  population.  Among  all  patients,  the  rate
of  out-of-hospital  major  adverse  cardiac  events  was  6.1%
(n  =  61):  death  from  cardiovascular  causes  occurred  in  24
(2.4%)  patients,  non-fatal  myocardial  infarction  in  10  (1.0%)
patients,  non-fatal  non-STEMI  in  seven  (0.7%)  patients,  non-
fatal  stroke  in  ﬁve  (0.5%)  patients,  fatal  stent  thrombosis  in
eight  (0.8%)  patients  and  non-fatal  stent  thrombosis  in  seven
(0.7%)  patients.  The  rate  of  stent  thrombosis  was  1.5%:  ﬁve
patients  had  a  deﬁnite  stent  thrombosis,  ﬁve  patients  had  a
probable  stent  thrombosis  and  ﬁve  patients  had  a  possible
stent  thrombosis.
Discussion
The  Bleed-MI  Study  allowed  evaluation  of  the  safety  of  pra-
sugrel  in  non-selected  STEMI  patients  in  a  real-world  setting,
according  to  bleeding  risk.  This  knowledge  is  crucial  for  the
clinician,  who  must  choose  the  best  antithrombotic  treat-
ment  and  its  optimal  duration  according  to  the  ischaemic
and  bleeding  risks.  The  ﬁnal  decision  concerning  an  indi-
vidual  patient  must  be  made  by  the  physician  responsible,
taking  into  account  the  beneﬁt/risk  balance,  as  stated  in
the  latest  European  Society  of  Cardiology  guidelines  for  the
management  of  STEMI  [3].
In  the  TRial  to  assess  Improvement  in  Therapeutic  Out-
comes  by  optimizing  platelet  inhibitioN  with  prasugrel-TIMI
(TRITON-TIMI  38)  [13],  patients  aged  ≥75  years  gained  no  net
beneﬁt  from  prasugrel,  and  there  were  no  statistically  signif-
icant  higher  rates  of  non-CABG-related  TIMI  major  bleeding
in  the  prasugrel  group  versus  the  clopidogrel  group  (4.3%
vs.  3.3%;  P  =  0.10).  In  the  Bleed-MI  Study,  patients  treated
with  prasugrel  had  more  BARC  2  bleeding  events  compared
with  patients  treated  with  clopidogrel,  but  fewer  BARC  3  or
5  bleedings.  This  low  risk  of  major  bleeding  in  prasugrel-
treated  patients  in  this  real-life  registry,  despite  frequent
use,  is  reassuring,  and  can  be  explained  by  the  selection
of  patient  candidates  for  prasugrel  (i.e.  those  with  a  lower
bleeding  risk).  This  means  that  the  contraindications  and
precautions  for  use  of  prasugrel  are  relevant.  Moreover,  it
means  that  physicians  are  using  the  drug  in  appropriate  can-
didates.  Nevertheless,  33  patients  (6.81%  of  patients  treated
with  prasugrel)  with  contraindications  or  precautions  for  use
of  prasugrel  received  prasugrel  in  the  study:  ﬁve  patients
with  a  history  of  stroke  or  transient  ischaemic  attack,  eight
patients  aged  ≥75  years,  13  patients  weighing  <60  kg  and
seven  patients  with  concomitant  use  of  a  VKA.
Unlike  many  studies,  we  included  non-selected  patients,
which  makes  our  results  useful  in  real-world  practice.  Most
studies  have  included  selected  patients  (patients  undergoing
PCI  for  STEMI,  for  example).  In  the  Bleed-MI  Study,  coronary
angiography  was  not  performed  in  22  (2%)  patients  and  no
angioplasty  was  performed  in  109  (10.1%)  patients;  these
patients  are  rarely  studied  in  randomized  trials.  Moreover,
we  focused  on  out-of-hospital  events:  in-hospital  bleeding,
often  related  to  procedural  bleeding  complications  (PCI  or
CABG),  should  be  differentiated  from  out-of-hospital  bleed-
ing.  The  rate  of  out-of-hospital  major  bleeding  within  1  year
after  a  STEMI  was  low  at  1.3%  according  to  the  BARC  def-
inition  and  at  0.6%  according  to  the  TIMI  deﬁnition.  The
rate  of  major  out-of-hospital  bleeding  was  particularly  low
b
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a37
n  patients  treated  with  prasugrel  because  of  the  accurate
election  of  patients.
The  chronology  of  major  bleeding  is  important  because
f  its  effect  on  the  duration  of  combination  antithrombotic
reatment  in  patients  with  a  high  bleeding  risk.  Bleeding
an  lead  to  transitory  or  permanent  discontinuation  of  one
r  more  antithrombotic  treatments,  with  the  risk  of  stent
hrombosis  in  stented  patients  and  ischaemic  complications
n  all  patients.  In  total,  68.3%  of  major  bleedings  occurred
uring  the  initial  hospitalization.  In  a  study  published  by  Col-
et  et  al.  [14]  in  2004,  5.4%  patients  admitted  for  a suspected
CS  had  recently  had  antiplatelet  agents  withdrawn,  which
as  found  to  be  an  independent  predictor  of  mortality  and
leeding  at  30  days.  In  the  Bleed-MI  Study,  out-of-hospital
leeding  (BARC  2,  3  or  5)  led  to  early  discontinuation  of
ny  thrombotic  agent  (before  6  months)  in  only  13  patients
16.5%  of  out-of-hospital  bleedings).  Moreover,  there  was
o  ischaemic  event  among  the  27  patients  who  discontinued
heir  treatment.  Bleeding  (including  minor  bleeding)  must
ot  be  underestimated,  and  should  be  systematically  sought
uring  the  medical  follow-up  of  patients  after  an  ACS,  as
his  would  promote  treatment  compliance.
The  reported  rates  of  major  bleedings  at  9—12  months’
ollow-up  after  an  ACS  vary  from  2  to  6%  [7,15—17].  In  the
leed-MI  Study,  in-hospital  and  out-of-hospital  major  bleed-
ng  occurred  in  3.8%  according  to  the  BARC  deﬁnition  and
n  1.5%  according  to  the  TIMI  deﬁnition.  In  TRITON-TIMI  38
13], the  rate  of  non-CABG-related  TIMI  major  bleeding  at
5  months  in  the  entire  population  was  2%.  Considering  only
atients  undergoing  PCI  for  STEMI  [4], the  risk  of  non-CABG
ajor  bleeding  was  lower,  at  1.1%,  which  is  close  to  our
ate  of  1.5%.  In  the  PLATO  study  [17],  the  rate  of  non-CABG-
elated  TIMI  major  bleedings  at  12  months  among  patients
ith  a  STEMI  was  2.2%.  Considering  the  location  of  bleed-
ngs  in  our  study,  the  most  frequent  out-of-hospital  major
leeding  sites  were  gastrointestinal,  but  the  most  frequent
ut-of-hospital  minor  bleeding  sites  were  ear,  nose  and
hroat  and  cutaneous,  while  the  most  severe  out-of-hospital
leeding  sites  were  cerebral.  In  the  Global  Registry  of  Acute
oronary  Events  [18],  the  most  common  life-threatening  in-
ospital  bleeding  complications  were  also  gastrointestinal.
tudy limitations
s  in  any  registry,  this  observational  study  has  some  lim-
tations.  For  instance,  26  patients  (2.5%)  were  lost  to
ollow-up.  The  follow-up  was  made  by  telephone  contact
t  3  months  and  at  1  year,  but  data  collection  was  done  by
ualiﬁed  hospital  staff  with  directed  questionnaires,  which
imits  the  loss  of  data.  Moreover,  BARC  1  bleedings  were
ot  collected  because  their  collection  would  not  have  been
xhaustive,  as  a  result  of  the  declaratory  nature  of  data
ollection,  and  premature  treatment  cessation  because  of
ARC  1  bleedings  could  not  have  been  analysed.
No  patient  was  treated  with  ticagrelor,  because  this
reatment  was  not  yet  available  in  Brittany  during  the  study.
According  to  an  analysis  from  the  TRITON-TIMI  38  study
19], independent  predictors  of  non-CABG-related  serious
leeding  throughout  15  months  were  female  sex,  use  of  a
lycoprotein  IIb/IIIa  inhibitor,  duration  of  intervention,  age,
ssignment  to  prasugrel  versus  clopidogrel,  STEMI,  femoral
ccess,  creatinine  clearance,  hypercholesterolaemia  and
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mortality: insights from the TRial to assess Improvement in8  
ypertension.  In  the  Bleed-MI  Study,  the  low  rate  of  major
ut-of-hospital  bleedings  reduced  the  statistical  power  for
etecting  clinical  and  biological  predictors  of  bleeding
vents.  Any  usual  predictors  of  bleeding  events  could  not
e  found,  and  no  statistical  association  between  the  occur-
ence  of  major  bleeding  and  mortality  was  demonstrated.
onclusion
ithin  1  year  after  a  STEMI,  the  major  bleeding  rate  in
atients  treated  with  prasugrel  is  low  when  patients  are
arefully  selected.  The  question  remains  of  extending  the
rescription  of  new  antiplatelet  agents  to  a  broader  pop-
lation  of  patients,  but  with  the  risk  of  modifying  the
eneﬁt-risk  balance  that  we  have  documented  in  real-world
elected  patients.
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